Xilio Therapeutics, Inc.
XLO
$0.709
$0.04757.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -58.24M | -62.80M | -65.53M | -70.96M | -76.40M |
| Total Depreciation and Amortization | 1.64M | 1.72M | 1.80M | 1.84M | 1.90M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.44M | 6.87M | 7.17M | 7.55M | 7.54M |
| Change in Net Operating Assets | 31.78M | 36.57M | 39.22M | 7.69M | -1.66M |
| Cash from Operations | -18.38M | -17.65M | -17.35M | -53.87M | -68.62M |
| Capital Expenditure | -36.00K | -30.00K | -21.00K | -316.00K | -486.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -36.00K | -30.00K | -21.00K | -316.00K | -486.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.38M | -5.07M | -7.31M | -8.42M | -6.75M |
| Issuance of Common Stock | 32.58M | 24.43M | 24.43M | 4.51M | 202.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 29.20M | 19.36M | 17.13M | -3.91M | -6.55M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.78M | 1.68M | -239.00K | -58.10M | -75.66M |
